Advertisement

Journal of Child and Family Studies

, Volume 23, Issue 4, pp 675–685 | Cite as

Reducing Psychotropic Medications in an Intensive Residential Treatment Center

  • Jonathan C. Huefner
  • Annette K. Griffith
  • Gail L. Smith
  • Dennis G. Vollmer
  • Laurel K. Leslie
Original Paper

Abstract

Medication rates in behaviorally disordered children and youth have greatly increased to current high levels and are very controversial. This study examined changes in psychotropic medication use, levels of behavioral disturbance, and use of personal restraint and seclusion in a population of youth with serious behavioral disorders receiving medically directed cognitive-behavioral treatment in an intensive residential setting. The hypothesis was that there would be significant reductions in medication rates, without the unintended consequences of increased rates of problem behavior or offsetting increases in the use of seclusion or personal restraint. Results showed significant reductions in both the number of youth on medication and the average number of psychotropic medications during the residential stay. There were also significant reductions in behavioral disturbance, seclusions, and personal restraints. These results demonstrate that psychotropic medication can be significantly reduced without increases in problem behavior or the use of seclusions or personal restraints. We conclude that it is possible to significantly reduce psychotropic medication rates to far more conservative levels within the context of a clinically directed cognitive-behavioral treatment milieu.

Keywords

Psychotropic medication Residential treatment Aggression Personal restraint Seclusion 

References

  1. Boxer, P. (2007). Aggression in very high-risk youth: Examining developmental risk in an inpatient psychiatric population. American Journal of Orthopsychiatry, 77, 636–646. doi: 10.1037/0002-9432.77.4.636.PubMedCrossRefGoogle Scholar
  2. Brown, R. T. (2005). Recent advances in pharmacotherapies for the externalizing disorders. School Psychology Quarterly, 20, 118–134. doi: 10.1521/scpq.20.2.118.66515.CrossRefGoogle Scholar
  3. Chamberlain, P., Price, J. M., Reid, J. B., Landsverk, J., Fisher, P. A., & Stoolmiller, M. (2006). Who disrupts from placement in foster and kinship care? Child Abuse and Neglect, 30, 409–424.PubMedCrossRefGoogle Scholar
  4. Chamberlain, P., & Reid, J. B. (1987). Parent observation and report of child symptoms. Behavioral Assessment, 9, 97–109.Google Scholar
  5. Chouinard, G. (2004). New nomenclature for drug-induced movement disorders including tardive dyskinesia. Journal of Clinical Psychiatry, 65, 9–15.PubMedGoogle Scholar
  6. Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Erlbaum.Google Scholar
  7. Connor, D. F., & McLaughlin, T. J. (2005). A naturalistic study of medication reduction in a residential treatment setting. Journal of Child and Adolescent Psychopharmacology, 15, 302–310. doi: 10.1089/cap.2005.15.302.PubMedCrossRefGoogle Scholar
  8. Connor, D. F., Ozbayrak, K. R., Harrison, R. J., & Melloni, R. H. J. (1998). Prevalence and patterns of psychotropic and anticonvulsant medication use in children and adolescents referred to residential treatment. Journal of Child and Adolescent Psychopharmacology, 8, 27–38. doi: 10.1016/S0031-9384(96)00373-3.PubMedCrossRefGoogle Scholar
  9. Connor, D. F., Ozbayrak, K. R., Kusiak, K. A., Caponi, A. B., & Melloni, R. H. (1997). Combined pharmacotherapy in children and adolescents in a residential treatment center. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 248–254. doi: 10.1097/00004583-199702000-00016.PubMedCrossRefGoogle Scholar
  10. Criste, T. R. (1989). Needs analysis at Western New York Children’s Psychiatric Center (Internal report). Boys Town, NE: Father Flanagan’s Boys’ Home.Google Scholar
  11. Daly, D. L., Schmidt, M. D., Spellman, D. F., Criste, T. R., Dinges, K., & Teare, J. F. (1998). The Boys Town Residential Treatment Center: Treatment implementation and preliminary outcomes. Child & Youth Care Forum, 27, 267–279.Google Scholar
  12. Dean, A. J., Duke, S. G., George, M., & Scott, J. (2007). Behavioral management leads to reduction in aggression in a child and adolescent psychiatric inpatient unit. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 711–720. doi: 10.1097/chi.0b013e3180465a1a.PubMedCrossRefGoogle Scholar
  13. Dean, A. J., McDermott, B. M., & Marshall, R. T. (2006). Psychotropic medication utilization in a child and adolescent mental health service. Journal of Child and Adolescent Psychopharmacology, 16, 273–285. doi: 10.1089/cap.2006.16.273.PubMedCrossRefGoogle Scholar
  14. dosReis, S., Zito, J. M., Safer, D. J., Gardner, J. F., Puccia, K. B., & Owens, P. L. (2005). Multiple psychotropic medication use for youths: A two-state comparison. Journal of Child and Adolescent Psychopharmacology, 15, 68–77.PubMedCrossRefGoogle Scholar
  15. Duffy, F. F., Narrow, W. E., Rae, D. S., West, J. C., Zarin, D. A., Rubio-Stipec, M., et al. (2005). Concomitant pharmacotherapy among youths treated in routine psychiatric practice. Journal of Child and Adolescent Psychopharmacology, 15, 12–25. doi: 10.1089/cap.2005.15.12.PubMedCrossRefGoogle Scholar
  16. Foltz, R. (2006). The mistreatment of mood disorders in youth. Ethical Human Psychology and Psychiatry: An International Journal of Critical Inquiry, 8, 147–155.CrossRefGoogle Scholar
  17. Fontanella, C. A., Bridge, J. A., & Campo, J. V. (2009). Psychotropic medication changes, polypharmacy, and the risk of early readmission in suicidal adolescent inpatients. The Annals of Pharmacotherapy, 43, 1939–1947. doi: 10.1345/aph.1M326.PubMedCrossRefGoogle Scholar
  18. Foxx, R. M. (1998). A comprehensive treatment program for inpatient adolescents. Behavioral Interventions, 13, 67–77.CrossRefGoogle Scholar
  19. Griffith, A. K., Huscroft-D’Angelo, J., Epstein, M. H., Singh, N. N., Huefner, J. C., & Pick, R. (2010). Psychotropic medication use for youth in residential treatment: A comparison between youth with monopharmacy versus polypharmacy. Journal of Child and Family Studies, 19, 795–802. doi: 10.1007/s10826-010-9372-9.CrossRefGoogle Scholar
  20. Griffith, A. K., Ingram, S. D., Barth, R. P., Trout, A. L., Duppong Hurley, K., Thompson, R. W., et al. (2009). The family characteristics of youth entering a residential care program. Residential Treatment for Children & Youth, 26, 135–150. doi: 10.1080/08865710902914283.CrossRefGoogle Scholar
  21. Gudjonsson, G. H., Rabe-Hesketh, S., & Wilson, C. (2000). Violent incidents on a medium secure unit: The target of assault and the management of incidents. Journal of Forensic Psychiatry, Francis, 11, 105–118. doi: 10.1080/095851800362391;10.1080/095851800362391.CrossRefGoogle Scholar
  22. Guevara, J., Lozano, P., Wickizer, T., Mell, L., & Gephart, H. (2002). Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder. Pediatrics, 109, 733–739.PubMedCrossRefGoogle Scholar
  23. Gullick, K., McDermott, B., Stone, P., & Gibbon, P. (2005). Seclusion of children and adolescents: Psychopathological and family factors. International Journal of Mental Health Nursing, 14, 37–43. doi: 10.1111/j.1440-0979.2005.00353.x;10.1111/j.1440-0979.2005.00353.x.PubMedCrossRefGoogle Scholar
  24. Haw, C., & Stubbs, J. (2007). Off-label use of antipsychotics: Are we mad? Expert Opinion on Drug Safety, 6, 533–545. doi: 10.1517/14740338.6.5.533.PubMedCrossRefGoogle Scholar
  25. Heflinger, C. A., & Humphreys, K. L. (2008). Identification and treatment of children with oppositional defiant disorder: A case study of one state’s public service system. Psychological Services, 5, 139–152. doi: 10.1037/1541-1559.5.2.139.CrossRefGoogle Scholar
  26. Hussey, D. L., & Guo, S. (2005). Forecasting length of stay in child residential treatment. Child Psychiatry and Human Development, 36, 95–111. doi: 10.1007/s10578-004-3490-9.PubMedCrossRefGoogle Scholar
  27. Kubiszyn, T. (2005). Introduction to the special issue: The Division 16 Task Force on Psychopharmacology, Learning and Behavior. School Psychology Quarterly, 20, 115–117.CrossRefGoogle Scholar
  28. Larzelere, R. E., Chmelka, M. B., Schmidt, M. D., & Jones, M. (2002). The Treatment Progress Checklist: Psychometric development of a daily symptom checklist. In C. Newman, C. J. Liberton, K. Kutash, & R. M. Friedman (Eds.), Proceedings of the 14th Annual Florida Mental Health Institute Conference (pp. 359–362). Tampa, FL: University of South Florida.Google Scholar
  29. LeFever, G. B., Arcona, A. P., & Antonuccio, D. O. (2003). ADHD among American schoolchildren evidence of overdiagnosis and overuse of medication. The Scientific Review of Mental Health Practice, 2, 49–60.Google Scholar
  30. Lekhwani, M., Nair, C., Nikhinson, I., & Ambrosini, P. J. (2004). Psychotropic prescription practices in child psychiatric inpatients 9 years old and younger. Journal of Child and Adolescent Psychopharmacology, 14, 95–103.PubMedCrossRefGoogle Scholar
  31. Leo, J. (2006). The truth about academic medicine: Children on psychotropic drugs and the illusion of science. In S. Timimi & B. Maitra (Eds.), Critical voices in child and adolescent mental health (pp. 107–127). London: Free Association Books.Google Scholar
  32. Lerer, B. (2002). Pharmacogenetics of psychotropic drugs. Cambridge, UK: Cambridge University Press.CrossRefGoogle Scholar
  33. Martin, A., Van Hoof, T., Stubbe, D., Sherwin, T., & Scahill, M. C. (2003). Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. Psychiatric Services, 54, 72–77. doi: 10.1176/appi.ps.54.1.72.PubMedCrossRefGoogle Scholar
  34. Najjar, F., Welch, C., Grapentine, W. L., Sachs, H., Siniscalchi, J., & Price, L. H. (2004). Trends in psychotropic drug use in a child psychiatric hospital from 1991–1998. Journal of Child and Adolescent Psychopharmacology, 14, 87–93. doi: 10.1089/104454604773840526.PubMedCrossRefGoogle Scholar
  35. Pappadopulos, E., MacIntyre, J. C., Crismon, M. L., Findling, R. L., Malone, R. P., Derivan, A., et al. (2003). Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 145–161. doi: 10.1097/00004583-200302000-00008.PubMedCrossRefGoogle Scholar
  36. Pappadopulos, E., Woolston, S., Chait, A., Perkins, M., Connor, D. F., & Jensen, P. S. (2006). Pharmacotherapy of aggression in children and adolescents: Efficacy and effect size. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 15, 27–39.PubMedCentralPubMedGoogle Scholar
  37. Pathak, S., Arszman, S. P., Danielyan, A., Johns, E. S., Smirnov, A., & Kowatch, R. A. (2004). Psychotropic utilization and psychiatric presentation of hospitalized very young children. Journal of Child and Adolescent Psychopharmacology, 14, 433–442. doi: 10.1089/cap.2004.14.433.PubMedCrossRefGoogle Scholar
  38. Pavkov, T. W., & Walrath, C. M. (2008). Clinical and non-clinical characteristics associated with medication use among children with serious emotional disturbance. Journal of Child and Family Studies, 17, 839–852. doi: 10.1007/s10826-008-9193-2.CrossRefGoogle Scholar
  39. Pelham, W. E., Burrows-MacLean, L., Gnagy, E. M., Fabiano, G. A., Coles, E. K., Tresco, K. E., et al. (2005). Transdermal methylphenidate, behavioral, and combined treatment for children With ADHD. Experimental and Clinical Psychopharmacology, 13, 111–126. doi: 10.1037/1064-1297.13.2.111;10.1037/1064-1297.13.2.111.PubMedCrossRefGoogle Scholar
  40. Pogge, D. L., Young, K., Insalaco, B., & Harvey, P. D. (2007). Use of atypical antipsychotic medications in adolescent psychiatric inpatients: A comparison with inpatients who did not receive antipsychotic medications during their stay. International Journal of Clinical Practice, 61, 896–902. doi: 10.1111/j.1742-1241.2007.01379.x.PubMedCrossRefGoogle Scholar
  41. Pottick, K. J., Warner, L. A., & Yoder, K. A. (2005). Youths living away from families in the US mental health system: Opportunities for targeted intervention. Journal of Behavioral Health Services & Research, 32, 264–281. doi: 10.1007/BF02291827.CrossRefGoogle Scholar
  42. Prinz, R. (2009). Dissemination of a multilevel evidence-based system of parenting interventions with broad application to child welfare populations. Child Welfare: Journal of Policy, Practice, and Program, 88, 127–132.Google Scholar
  43. Rawal, P. H., Lyons, J. S., MacIntyre, J. C., I. I., & Hunter, J. C. (2004). Regional variation and clinical indicators of antipsychotic use in residential treatment: A four-state comparison. Journal of Behavioral Health Services & Research, 31, 178–188.Google Scholar
  44. Safer, D. J., Zito, J. M., & dosReis, S. (2003). Concomitant psychotropic medication for youths. American Journal of Psychiatry, 160, 438–449. doi: 10.1176/appi.ajp.160.3.438.PubMedCrossRefGoogle Scholar
  45. Schachter, H. M., Pham, B., King, J., Langford, S., & Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Canadian Medical Association Journal, 165, 1475–1488.PubMedCentralPubMedGoogle Scholar
  46. Singh, N. N., Landrum, T. J., Donatelli, L. S., & Hampton, C. (1994). Characteristics of children and adolescents with serious emotional disturbance in systems of care: I. Partial hospitalization and inpatient psychiatric services. Journal of Emotional and Behavioral Disorders, 2, 13–20.CrossRefGoogle Scholar
  47. Spellman, D. F., Griffith, A. K., Huefner, J. C., Wise, N., III, McElderry, E., & Leslie, L. K. (2010). Psychotropic medication management in a residential group care program. Child Welfare, 89, 151–167.PubMedGoogle Scholar
  48. Sukhodolsky, D. G., Cardona, L., & Martin, A. (2005). Characterizing aggressive and noncompliant behaviors in a children’s psychiatric inpatient setting. Child Psychiatry and Human Development, 36, 177–193. doi: 10.1007/s10578-005-3494-0.PubMedCrossRefGoogle Scholar
  49. Swanson, J., Arnold, L. E., Kraemer, H., Hechtman, L., Molina, B., Hinshaw, S., et al. (2008). Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of children with ADHD (MTA): Part I: Executive summary. Journal of Attention Disorders, 12, 4–14. doi: 10.1177/1087054708319345.PubMedCrossRefGoogle Scholar
  50. Timimi, S., & Maitra, B. (2006). New directions. In S. Timimi & B. Maitra (Eds.), Critical voices in child and adolescent mental health (pp. 222–228). London: Free Association Books.Google Scholar
  51. Trout, A. L., Hagaman, J., Casey, K., Reid, R., & Epstein, M. H. (2008). The academic status of children and youth in out-of-home care: A review of the literature. Children and Youth Services Review, 30, 979–994.CrossRefGoogle Scholar
  52. Van Bellinghen, M., & De Troch, C. (2001). Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology, 11, 5–13. doi: 10.1089/104454601750143348.PubMedCrossRefGoogle Scholar
  53. Vitiello, B. (2005). Pharmacoepidemiology and pediatric psychopharmacology research. Journal of Child and Adolescent Psychopharmacology, 15, 10–11. doi: 10.1089/cap.2005.15.10.PubMedCrossRefGoogle Scholar
  54. Vitiello, B., Rohde, P., Silva, S., Wells, K., Casat, C., Waslick, B., et al. (2006). Functioning and quality of life in the Treatment for Adolescents With Depression Study (TADS). Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1419–1426. doi: 10.1097/01.chi.0000242229.52646.6e.PubMedCrossRefGoogle Scholar
  55. Warner, L. A., Fontanella, C. A., & Pottick, K. J. (2007). Initiation and change of psychotropic medication regimens among adolescents in inpatient care. Journal of Child and Adolescent Psychopharmacology, 17, 701–712. doi: 10.1089/cap.2007.0120.PubMedCrossRefGoogle Scholar
  56. Woolston, J. L. (1999). Combined pharmacotherapy: Pitfalls of treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 1455–1457. doi: 10.1097/00004583-199911000-00021.PubMedCrossRefGoogle Scholar
  57. Zakriski, A. L., Wheeler, E., Burda, J., & Shields, A. (2005). Justifiable psychopharmacology or overzealous prescription? Examining parental reports of lifetime prescription histories of psychiatrically hospitalised children. Child and Adolescent Mental Health, 10, 16–22. doi: 10.1111/j.1475-3588.2005.00111.x.CrossRefGoogle Scholar
  58. Zito, J. M., Craig, T. J., & Wanderling, J. (1994). Pharmacoepidemiology of 330 child/adolescent psychiatric patients. Journal of Pharmacoepidemiology, 3, 47–62. doi: 10.1300/J055V03N01_04.CrossRefGoogle Scholar
  59. Zito, J. M., Safer, D. J., Sai, D., Gardner, J. F., Thomas, D., Coombes, P., et al. (2008). Psychotropic medication patterns among youth in foster care. Pediatrics, 121, 157–163. doi: 10.1542/peds.2007-0212.CrossRefGoogle Scholar
  60. Zito, J. M., Safer, D. J., Zuckerman, I. H., Gardner, J. F., & Soeken, K. (2005). Effect of medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. Psychiatric Services, 56, 157–163.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Jonathan C. Huefner
    • 1
  • Annette K. Griffith
    • 2
  • Gail L. Smith
    • 1
  • Dennis G. Vollmer
    • 3
  • Laurel K. Leslie
    • 4
  1. 1.Boys Town National Research Institute for Child and Family StudiesBoys TownUSA
  2. 2.Momentum Behavioral HealthLee’s SummitUSA
  3. 3.Boys Town National Research HospitalOmahaUSA
  4. 4.Tufts Medical CenterBostonUSA

Personalised recommendations